Hospital
Renown South Meadows Medical Center
Renown South Meadows Medical Center was paid $7.26M by Medicaid between Jan 2018 and Dec 2024, across 184 billing codes. Its largest line is 99284, emergency room visit (serious) — 20% of everything it billed.
33Billing provider infoRENOWN SOUTH MEADOWS MEDICAL CENTER
RENO, NV 89521
RENO, NV 89521
33aNPI1720058027assigned 01/26/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.26M
24GClaims370,074
24DCodes billed184
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Nevada
Rank by total paid#20 of 36
Median peer was paid$7.64M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MOORE, BRETT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 22,232 | $377K | |
| 2019 | 57,136 | $1.12M | |
| 2020 | 52,250 | $1.05M | |
| 2021 | 72,798 | $1.22M | |
| 2022 | 62,112 | $1.17M | |
| 2023 | 56,785 | $1.24M | |
| 2024incomplete | 46,761 | $1.08M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 15,859 | 13,601 | $1.46M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 7,914 | 6,700 | $1.14M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 14% | 23,435 | 8,565 | $1.00M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 7.3% | 3,075 | 2,791 | $531K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.7% | 9,680 | 8,590 | $486K |
| G0378 | Hospital observation service, per hour | 4.5% | 2,152 | 1,749 | $324K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 3.3% | 7,157 | 2,840 | $242K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.2% | 8,584 | 7,166 | $159K |
| 97162 | 1.9% | 2,546 | 2,440 | $138K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.7% | 1,383 | 1,314 | $123K |
| 97161 | 1.6% | 2,152 | 2,048 | $115K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 7,373 | 5,675 | $89K |
172 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 1,895 | $77K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,780 | $72K |
| 80053 | Comprehensive metabolic panel | <1% | 19,610 | $69K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 897 | $65K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,656 | $64K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,739 | $56K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 19,829 | $49K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 864 | $48K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 333 | $46K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,016 | $41K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,988 | $40K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,674 | $35K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,585 | $33K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 494 | $32K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,180 | $32K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,039 | $32K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,308 | $31K |
| 97014 | <1% | 2,940 | $29K | |
| 76830 | Ultrasound, transvaginal | <1% | 396 | $29K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 570 | $20K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 250 | $19K |
| 36415 | Collection of venous blood by venipuncture | <1% | 21,858 | $19K |
| 97163 | <1% | 323 | $19K | |
| 83690 | <1% | 7,236 | $18K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,959 | $18K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,184 | $17K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 942 | $17K |
| 84484 | <1% | 5,868 | $17K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 875 | $15K |
| 96376 | <1% | 2,654 | $15K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,316 | $15K |
| 84703 | <1% | 4,466 | $13K | |
| 97116 | <1% | 786 | $13K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,978 | $13K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 69 | $13K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 752 | $12K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 752 | $12K |
| 94060 | <1% | 295 | $11K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 647 | $11K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 120 | $11K |
| 83605 | <1% | 2,928 | $10K | |
| 93971 | <1% | 199 | $9K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,076 | $9K |
| 83880 | <1% | 1,067 | $8K | |
| C1776 | Joint device (implantable) | <1% | 27 | $8K |
| 80061 | Lipid panel | <1% | 1,984 | $8K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 432 | $7K |
| 87040 | <1% | 2,299 | $7K | |
| 97165 | <1% | 206 | $7K | |
| 94726 | <1% | 228 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 484 | $6K |
| 81001 | <1% | 5,254 | $6K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,241 | $6K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,404 | $5K |
| 72100 | <1% | 293 | $5K | |
| 94729 | <1% | 212 | $5K | |
| 64447 | <1% | 173 | $5K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,863 | $5K |
| 85027 | <1% | 3,268 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,629 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,532 | $4K |
| 81025 | <1% | 2,000 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,321 | $4K |
| J3490 | Unclassified drugs | <1% | 2,150 | $3K |
| 73030 | <1% | 266 | $3K | |
| 74018 | <1% | 232 | $3K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 42 | $3K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,089 | $3K |
| 94760 | <1% | 3,539 | $3K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 478 | $3K |
| 85379 | <1% | 800 | $3K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 25 | $3K |
| 81003 | <1% | 3,680 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 471 | $3K |
| 83735 | <1% | 1,657 | $3K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 207 | $3K |
| 84702 | <1% | 422 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,205 | $3K |
| 85730 | <1% | 1,589 | $2K | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 1,644 | $2K |
| 73630 | <1% | 171 | $2K | |
| 82077 | <1% | 497 | $2K | |
| 84439 | <1% | 1,126 | $2K | |
| 0450 | Emergency room services | <1% | 57 | $2K |
| 85610 | <1% | 2,443 | $2K | |
| 73610 | <1% | 119 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,997 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,237 | $2K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 46 | $2K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 13 | $2K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 14 | $2K |
| 97012 | <1% | 205 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 120 | $2K |
| 86780 | <1% | 271 | $2K | |
| 82962 | <1% | 3,277 | $2K | |
| 86140 | <1% | 897 | $2K | |
| 76801 | <1% | 28 | $2K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,006 | $1K |
| 71250 | <1% | 16 | $1K | |
| 87077 | <1% | 550 | $1K | |
| 87641 | <1% | 117 | $1K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 59 | $1K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,447 | $1K |
| 99152 | <1% | 305 | $1K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 564 | $1K |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 380 | $1K |
| 76536 | <1% | 13 | $1K | |
| 87081 | <1% | 328 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,794 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 3,587 | $965.17 |
| 86901 | <1% | 707 | $735.52 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 40 | $723.22 |
| 87186 | <1% | 247 | $655.26 | |
| 73562 | <1% | 31 | $641.64 | |
| 85652 | <1% | 766 | $634.77 | |
| 86900 | <1% | 154 | $614.40 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 587 | $611.24 |
| 82607 | <1% | 149 | $583.22 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 853 | $523.53 |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 15 | $522.70 |
| 73130 | <1% | 33 | $515.49 | |
| 76775 | <1% | 19 | $486.88 | |
| 87640 | <1% | 101 | $486.15 | |
| 73110 | <1% | 30 | $481.29 | |
| 84145 | <1% | 74 | $479.59 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 118 | $463.73 |
| 86803 | <1% | 88 | $453.94 | |
| 80305 | <1% | 117 | $441.56 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 828 | $421.56 |
| 64415 | <1% | 14 | $399.70 | |
| 72040 | <1% | 27 | $365.42 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 44 | $288.86 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 161 | $228.55 |
| 82728 | <1% | 42 | $225.92 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,217 | $199.83 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 298 | $199.63 |
| 82570 | <1% | 184 | $179.31 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 198 | $171.29 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 28 | $149.92 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 99 | $147.29 |
| 83540 | <1% | 80 | $143.93 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 99 | $139.47 |
| 96367 | <1% | 25 | $133.45 | |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 127 | $111.45 |
| 86850 | <1% | 62 | $88.63 | |
| 84100 | <1% | 82 | $81.56 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 42 | $78.49 |
| 87070 | <1% | 14 | $59.18 | |
| 87400 | <1% | 50 | $48.71 | |
| 83550 | <1% | 27 | $47.80 | |
| 82043 | <1% | 57 | $47.40 | |
| 84481 | <1% | 12 | $42.85 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 56 | $42.24 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 15 | $37.50 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 71 | $36.80 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 158 | $34.04 |
| 82550 | <1% | 19 | $26.44 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 52 | $22.02 |
| 81002 | <1% | 46 | $19.66 | |
| 85007 | <1% | 15 | $15.87 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 173 | $5.91 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,225 | $2.57 |
| A9270 | Non-covered item or service | <1% | 15,523 | $1.50 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 101 | $0.60 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 12 | $0.20 |
| A6222 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 45 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 40 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 489 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 133 | $0.00 |
| 90715 | 0% | 13 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 44 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 165 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMOORE, BRETT (CFO ACUTE CARE)
| Provider | Location | Paid |
|---|---|---|
| Renown Regional Medical Center | Reno, NV | $63.69M |
| Community Care Services LLC | Reno, NV | $15.07M |
| Renown Medical School Associates North, INC. | Reno, NV | $5.43M |
| Community Care Services LLC | Reno, NV | $3.79M |
| Community Care Services LLC | Reno, NV | $2.60M |
| Hometown Health Management Company | Reno, NV | $1.69M |
| Eastern Sierra Medical Group LLC | Silver Springs, NV | $1.08M |
| Community Care Services LLC | Reno, NV | $1.07M |
| Community Care Services LLC | Reno, NV | $1.04M |
| Hometown Health Management Company | Sparks, NV | $849K |
| Community Care Services LLC | Fernley, NV | $845K |
| Renown Regional Medical Center | Reno, NV | $677K |
| Community Care Services LLC | Reno, NV | $530K |
| Community Care Services LLC | Reno, NV | $455K |
| Renown Transitional Care Services | Reno, NV | $420K |
| Community Care Services LLC | Reno, NV | $331K |
| Community Care Services LLC | Reno, NV | $293K |
| Community Care Services LLC | Reno, NV | $225K |
| Community Care Services LLC | Reno, NV | $102K |
| Community Care Services LLC | Reno, NV | $76K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.